Deborah Mash is the CEO and Founder of DemeRx, Inc., a clinical stage drug development company advancing ibogaine and its active metabolite noribogaine for the treatment of opioid use disorder. DemeRx partnered in 2019 with ATAI Life Sciences — a global biotech platform — to develop ibogaine for those suffering from opioid use disorder.
Deborah is a neuroscientist, lecturer, and inventor who has dedicated more than 30 years of research to unlocking the secrets of the human brain. She is nationally recognized as a leading neuroscience researcher, playing a pivotal role in over 300 published studies investigating aging, neurodegenerative and psychiatric disorders, drug development, and addiction neurobiology. She is the founder and former director of the University of Miami Brain Endowment Bank, one of the six NIH funded NeuroBioBanks. She has held uninterrupted Public Health Service NIH funding to advance research studies focused on the role of the human brain in health and disease.
